Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05943938
Other study ID # STUDY00005958
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date August 2024
Est. completion date December 2024

Study information

Verified date May 2024
Source Emory University
Contact Sivasubramanium Bhavani, MD
Phone 404-712-2970
Email sivasubramanium.bhavani@emory.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Sepsis is a severe response to infection resulting in organ dysfunction and often leading to death. More than 1.5 million people get sepsis every year in the U.S., and 270,000 Americans die from sepsis annually. Delays in the diagnosis of sepsis lead to increased mortality. Several clinical decision support algorithms exist for the early identification of sepsis. The research team will compare the performance of three sepsis prediction algorithms to identify the algorithm that is most accurate and clinically actionable. The algorithms will run in the background of the electronic health record (EHR) and the predictions will not be revealed to patients or clinical staff. In this current evaluation study, the algorithms will not affect any part of a patient's care. The algorithms will be deployed across the Emory healthcare system on data from all patients presenting to the emergency department.


Description:

The primary goal of this study is to prospectively evaluate three sepsis prediction algorithms that are embedded in the EHR. The models will be deployed in a "shadow" mode, and the results will not be displayed to the treatment team during this study. Two of the algorithms are proprietary algorithms of the EHR provider (Epic). The third algorithm is an internally developed, open-source algorithm. The algorithms will compute the probability of sepsis at periodic intervals and will continue to run on a patient's data until the patient's discharge, death, or upon initiation of intravenous antibiotics (at which point there is an indirect record of clinical suspicion of an infection).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1200
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All adult patients admitted through the ED Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Epic Sepsis Model Version - 1
The Epic Sepsis Model (ESM) version 1, a proprietary sepsis prediction model.
Epic Sepsis Model Version - 2
The Epic Sepsis Model (ESM) version 2, a proprietary sepsis prediction model.
Emory Sepsis Model
Emory internal algorithm

Locations

Country Name City State
United States Emory Healthcare System Atlanta Georgia
United States Emory Hospital Atlanta Georgia
United States Emory Midtown Hospital Atlanta Georgia
United States Emory Saint Joseph's Hospital Atlanta Georgia
United States Emory Decatur Hospital Decatur Georgia
United States Emory Johns Creek Hospital Johns Creek Georgia
United States Emory Hillandale Hospital Lithonia Georgia

Sponsors (1)

Lead Sponsor Collaborator
Emory University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient hospitalization-level area under curve (AUC) for identification of sepsis, Definition of Sepsis using the Centers for Disease Control and Prevention (CDC) Adult Sepsis Surveillance. Duration of hospital stay (until discharge or death), an expected average of 30 days
Secondary Sensitivity, specificity, and Positive and Negative Predictive Value of algorithms Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Duration of hospital stay (until discharge or death), an expected average of 30 days
Secondary Lead time to antibiotic administration The time between the initial deployment of the alert in patients confirmed to have sepsis (ture positives) and the physician's ordering of intravenous antibiotic therapy. Duration of hospital stay (until discharge or death), an expected average of 30 days
Secondary Percent expected increase in unnecessary antibiotics Percent of patients who were incorrectly identified as having sepsis (false positives), and received antibiotics. Duration of hospital stay (until discharge or death), an expected average of 30 days
Secondary Number needed to screen The number of alerts that would need to be processed to find one true positive sepsis. Duration of hospital stay (or death), an expected average of 30 days
Secondary Number of Total and false alert burden The number of Total and false alert burden cumulative across all study patients over the study period Duration of hospital stay (until discharge or death), an expected average of 30 days
Secondary Time-horizon based AUCs AUCs will be calculated at 3 pre-specified time horizons. 4 hours, 8 hours, and 24 hours
Secondary Accuracy and calibration by subgroup The AUC and calibration curves will be compared by sex and race to ensure predictive accuracy is equal across subgroups. Duration of hospital stay (until discharge or death), an expected average of 30 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3